Table 1.

Primary and secondary outcome parameter results (data as estimate ± standard error from the lme model)

Parameter	Modality	HS		GERD
		Placebo	PPI	Placebo	PPI
mean SV [ml]	MRI	133 ± 14	73 ± 14*	152 ± 14	66 ± 14*
max SV [ml]	MRI	193 ± 17	100 ± 18*	227 ± 18	94 ± 17*
Layer thickness at 60 min [mm]	MRI	26 ± 5	7 ± 5*	36 ± 5	9 ± 5*
Layer Volume at 60 min [ml]	MRI	79 ± 16	20 ± 16*	117 ± 17	18 ± 17*
Median mingastricph	pH-monitoring	1.8 ± 0.3	4.5 ± 0.3*	1.5 ± 0.3	3.8 ± 0.3*
2 h postprandial
t50 [min]	MRI	60 ± 6	71 ± 6	62 ± 6	64 ± 6
EGJ exposure time to ≥ 70 % secretion layer Normalized to T50	MRI	0.45 ± 0.2	0.42 ± 0.2	1.18 ± 0.2***	0.42 ± 0.2**
Eraflux symptoms score	Questionnaire	0 ± 0	0 ± 0	33 ± 3	20 ± 3*

* <0.05, ** p < 0.01 different to placebo

*** <0.05, p < 0.01 different to HS

Poisson distributed parameter